Today's After-Hours Stock Movers:

Infrastructure and Energy Alternatives, Inc. (NASDAQ: IEA) 19.4% HIGHER; announced a joint venture with F.H. Paschen for the West Lake Corridor rail expansion awarded by the Northern Indiana Commuter Transportation District (NICTD) and valued at over $550 million. The contract was secured by Ragnar Benson, a subsidiary of IEA that provides heavy- and light-rail construction, and F.H. Paschen, a general contractor and construction manager with over 110 years of experience in the construction industry.

SolarEdge Technologies (NASDAQ: SEDG) 19% LOWER; reported Q3 EPS of $1.21, $0.39 better than the analyst estimate of $0.82. Revenue for the quarter came in at $338.1 million versus the consensus estimate of $342.33 million. SolarEdge Technologies sees Q4 2020 revenue of $345-365 million, versus the consensus of $389.6 million.

Arista Networks (NYSE: ANET) 10.3% HIGHER; reported Q3 EPS of $2.42, $0.21 better than the analyst estimate of $2.21. Revenue for the quarter came in at $605.4 million versus the consensus estimate of $581.33 million. Arista Networks sees Q4 2020 revenue of $615-635 million, versus the consensus of $609.25 million.

Inspire Medical Systems (NYSE: INSP) 10% HIGHER; reported Q3 EPS of ($0.39), $0.33 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $35.8 million versus the consensus estimate of $22.75 million. Inspire Medical Systems sees FY2020 revenue of $110-112 million, versus the consensus of $90.19 million.

Jazz Pharmaceuticals (NASDAQ: JAZZ) 8% HIGHER; reported Q3 EPS of $4.31, $0.23 better than the analyst estimate of $4.08. Revenue for the quarter came in at $600.89 million versus the consensus estimate of $577.58 million.

Cirrus Logic, Inc. (NASDAQ: CRUS) 8% HIGHER; reported Q2 EPS of $1.26, $0.36 better than the analyst estimate of $0.90. Revenue for the quarter came in at $347.3 million versus the consensus estimate of $310.56 million. Cirrus Logic, Inc. sees Q3 2021 revenue of $440-480 million, versus the consensus of $354.4 million.

Halozyme Therapeutics (NASDAQ: HALO) 7.8% HIGHER; reported Q3 EPS of $0.25, $0.06 better than the analyst estimate of $0.19. Revenue for the quarter came in at $65.3 million versus the consensus estimate of $60.9 million. Halozyme Therapeutics sees FY2020 EPS of $0.80-$0.85, versus the consensus of $0.69. Halozyme Therapeutics sees FY2020 revenue of $250-260 million, versus the consensus of $235.94 million.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) 7.6% HIGHER; Announced positive top-line results from the Phase 3 portion of the randomized, double blind, placebo controlled, cross-over, SEAL study evaluating single agent, oral XPOVIO® (selinexor) versus matching placebo in patients with advanced unresectable dedifferentiated liposarcoma. The SEAL study met its primary endpoint of a statistically significant increase in progression-free survival (PFS); hazard ratio=0.70; p=0.023. These data indicate that treatment with XPOVIO reduced the risk of disease progression or death by approximately 30%, compared to placebo. The trial allowed patients on placebo with objective progression to cross over to the XPOVIO treatment arm. Among those patients who received XPOVIO, there was a trend towards an improvement in the median overall survival compared to those patients who began on the placebo arm of the study and never crossed over to the XPOVIO treatment arm. The safety profile for XPOVIO was consistent with previous clinical studies with fewer hematologic and infectious adverse events as compared to XPOVIO studies in patients with multiple myeloma and diffuse large B-cell lymphoma (DLBCL).

J2 Global (NASDAQ: JCOM) 5.8% HIGHER; reported Q3 EPS of $2.02, $0.25 better than the analyst estimate of $1.77. Revenue for the quarter came in at $357 million versus the consensus estimate of $338.82 million. J2 Global sees FY2020 EPS of $7.85-$8.00, versus the consensus of $7.28. J2 Global sees FY2020 revenue of $1.447-1.462 billion, versus the consensus of $1.39 billion.

PayPal (NASDAQ: PYPL) 5.8% LOWER; reported Q3 EPS of $1.07, $0.13 better than the analyst estimate of $0.94. Revenue for the quarter came in at $5.46 billion versus the consensus estimate of $5.43 billion.

NeoPhotonics (NYSE: NPTN) 5.5% LOWER; reported Q3 EPS of $0.11, in-line with the analyst estimate of $0.11. Revenue for the quarter came in at $102.4 million versus the consensus estimate of $101.67 million.